Terms: = Kidney tumors AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Clinical Outcome
4 results:
1. Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution.
Chan E; Stohr BA; Croom NA; Cho SJ; Garg K; Troxell ML; Higgins JP; Bean GR
Histopathology; 2020 Jun; 76(7):1084-1090. PubMed ID: 32064677
[TBL] [Abstract] [Full Text] [Related]
2. Immunohistochemical study of cyclin A and p16 expression in patients with renal cell carcinoma.
Latic D; Radojevic-Skodric S; Nikolic S; Prvanovic M; Lazic M; Dzamic Z; Bogdanovic L; Radunovic M; Vukovic M
J BUON; 2017; 22(5):1322-1327. PubMed ID: 29135120
[TBL] [Abstract] [Full Text] [Related]
3. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract] [Full Text] [Related]
4. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract] [Full Text] [Related]